US 12,064,418 B2
Conjoint therapies for immunomodulation
Pottayil Govindan N. Sasikumar, Bangalore (IN); Muralidhara Ramachandra, Bangalore (IN); Raghuveer K. Ramachandra, Bengaluru (IN); Adam S. Lazorchak, Arlington, MA (US); and Timothy L. Wyant, Bellingham, MA (US)
Assigned to Curis, Inc., Lexington, MA (US); and Aurigene Oncology Limited, Bangalore (IN)
Filed by Aurigene Oncology Limited, Bangalore (IN); and Curis, Inc., Lexington, MA (US)
Filed on Oct. 5, 2022, as Appl. No. 17/960,586.
Application 17/960,586 is a continuation of application No. 16/761,964, granted, now 11,497,735, previously published as PCT/IB2018/058533, filed on Oct. 31, 2018.
Claims priority of application No. 201741039497 (IN), filed on Nov. 6, 2017.
Prior Publication US 2023/0081191 A1, Mar. 16, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4245 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01)
CPC A61K 31/4245 (2013.01) [A61P 35/00 (2018.01); A61K 45/06 (2013.01)] 15 Claims
 
1. A method of treating cancer in a subject in need thereof comprising conjointly administering a first compound and a second compound to the subject, wherein
the first compound is:

OG Complex Work Unit Chemistry
 or a pharmaceutically acceptable salt thereof; and
the second compound is

OG Complex Work Unit Chemistry
 or a pharmaceutically acceptable salt thereof.